Pravastatin and Lovastatin Similarly Reduce Serum Cholesterol and Its Precursor Levels in Familial Hypercholesterolaemia

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1992 Jan 1

PMID 1618241

Citations 3

Authors

H Vanhanen

T A Miettinen

Affiliations

Soon will be listed here.

Abstract

The hypocholesterolaemic effect of pravastatin 40 mg and lovastatin 40 mg daily has been compared in patients with familial hypercholesterolaemia (FH). Administration of the two drugs was separated by a three-month washout period. The reduction in total serum cholesterol after 1,2 and 4 weeks of treatment was similar after pravastatin (-23%, -32% and -32%) and lovastatin (-23%, -30% and -31%). The serum concentrations of LDL cholesterol were similarly reduced, whilst triglycerides, other lipoproteins, cholestanol and squalene were not altered. The reductions in the serum levels of the cholesterol precursor sterols, delta 8-cholesterol, desmosterol and lathosterol were not significantly different after either drug. The lack of difference suggests that cholesterol synthesis was equally inhibited by the two agents. In addition, the serum content of the plant sterols campesterol and sitosterol tended to be equally increased. The comparability of the increases suggests that the absorption and biliary elimination of the two sterols were equally affected by the two statins. Thus, no difference was found between the effects of pravastatin and lovastatin on the serum levels and metabolic precursors of cholesterol in FH during four weeks of treatment.

Citing Articles

Influence of previous statin therapy on cholesterol-lowering effect of ezetimibe.

Choi Y, Kim Y, Hyeon C, Hyun S, Kwon J, Won H Korean Circ J. 2014; 44(4):227-32.

PMID: 25089134 PMC: 4117843. DOI: 10.4070/kcj.2014.44.4.227.

Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients.

Thongtang N, Lin J, Schaefer E, Lowe R, Tomassini J, Shah A Atherosclerosis. 2012; 225(2):388-96.

PMID: 23040830 PMC: 3749834. DOI: 10.1016/j.atherosclerosis.2012.09.001.

Phytosterols and phytosterolemia: gene-diet interactions.

Izar M, Tegani D, Kasmas S, Fonseca F Genes Nutr. 2011; 6(1):17-26.

PMID: 21437027 PMC: 3040800. DOI: 10.1007/s12263-010-0182-x.

References

FRIEDEWALD W, Levy R, Fredrickson D . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6):499-502. View

Miettinen T, Tilvis R, Kesaniemi Y . Serum cholestanol and plant sterol levels in relation to cholesterol metabolism in middle-aged men. Metabolism. 1989; 38(2):136-40. DOI: 10.1016/0026-0495(89)90252-7. View

Germershausen J, HUNT V, Bostedor R, Bailey P, KARKAS J, ALBERTS A . Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem Biophys Res Commun. 1989; 158(3):667-75. DOI: 10.1016/0006-291x(89)92773-3. View

Ishida F, Sato A, Iizuka Y, Kitani K, SAWASAKI Y, Kamei T . Effects of MK-733 (simvastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on intestinal acylcoenzyme A:cholesterol acyltransferase activity in rabbits. Biochim Biophys Acta. 1989; 1004(1):117-23. DOI: 10.1016/0005-2760(89)90221-x. View

Saito Y, Goto Y, Nakaya N, Hata Y, Homma Y, Naito C . Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test. Atherosclerosis. 1988; 72(2-3):205-11. DOI: 10.1016/0021-9150(88)90082-2. View

Ishida F, Watanabe K, Sato A, Taguchi K, Kakubari K, Kitani K . Comparative effects of simvastatin (MK-733) and pravastatin (CS-514) on hypercholesterolemia induced by cholesterol feeding in rabbits. Biochim Biophys Acta. 1990; 1042(3):365-73. DOI: 10.1016/0005-2760(90)90166-u. View

ALBERTS A . Discovery, biochemistry and biology of lovastatin. Am J Cardiol. 1988; 62(15):10J-15J. DOI: 10.1016/0002-9149(88)90002-1. View

Vega G, Krauss R, Grundy S . Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins. J Intern Med. 1990; 227(2):81-94. DOI: 10.1111/j.1365-2796.1990.tb00124.x. View

Reihner E, Rudling M, Stahlberg D, Berglund L, Ewerth S, Bjorkhem I . Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med. 1990; 323(4):224-8. DOI: 10.1056/NEJM199007263230403. View

10.

de Rooy F, Jansen H, van Blankenstein M . Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia. Gut. 1990; 31(3):348-50. PMC: 1378282. DOI: 10.1136/gut.31.3.348. View

11.

Grundy S . HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988; 319(1):24-33. DOI: 10.1056/NEJM198807073190105. View

12.

Miettinen T, Tilvis R, Kesaniemi Y . Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol. 1990; 131(1):20-31. DOI: 10.1093/oxfordjournals.aje.a115479. View

13.

ALBERTS A, Chen J, Kuron G, Hunt V, Huff J, Hoffman C . Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A. 1980; 77(7):3957-61. PMC: 349746. DOI: 10.1073/pnas.77.7.3957. View

14.

DUGGAN D, CHEN I, Bayne W, Halpin R, Duncan C, SCHWARTZ M . The physiological disposition of lovastatin. Drug Metab Dispos. 1989; 17(2):166-73. View

15.

Uauy R, Vega G, Grundy S, Bilheimer D . Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover. J Pediatr. 1988; 113(2):387-92. DOI: 10.1016/s0022-3476(88)80289-0. View

16.

Ishida F, Sato A, Iizuka Y, Kamei T . Inhibition of acyl coenzyme A: cholesterol acyltransferase by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Chem Pharm Bull (Tokyo). 1989; 37(6):1635-6. DOI: 10.1248/cpb.37.1635. View

17.

Miettinen T . Diurnal variation of cholesterol precursors squalene and methyl sterols in human plasma lipoproteins. J Lipid Res. 1982; 23(3):466-73. View

18.

Henwood J, Heel R . Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs. 1988; 36(4):429-54. DOI: 10.2165/00003495-198836040-00003. View

19.

Mosley S, Kalinowski S, Schafer B, Tanaka R . Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens. J Lipid Res. 1989; 30(9):1411-20. View

20.

Hoffman W, ALBERTS A, Anderson P, Chen J, Smith R, Willard A . 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin. J Med Chem. 1986; 29(5):849-52. DOI: 10.1021/jm00155a040. View